-
Article
Pharmacokinetic–Pharmacodynamic–Efficacy Analysis of Efalizumab in Patients with Moderate to Severe Psoriasis
Efalizumab is a humanized anti-CD11a monoclonal antibody that demonstrated efficacy in the treatment of patients with psoriasis. The objective of this study was to perform a pharmacokinetic (PK)–pharmacodynami...
-
Article
A CD14-independent LPS receptor cluster
Bacterial lipopolysaccharide (LPS), the major structural component of the outer wall of Gram-negative bacteria, is a potent initiator of an inflammatory response and serves as an indicator of bacterial infecti...
-
Article
Population Pharmacokinetics and Pharmacodynamics of the Anti-CD11a Antibody hu1124 in Human Subjects with Psoriasis
The pharmacokinetics of hu1124, a human anti-CD11a antibody, were investigated in human subjects with psoriasis. CD11a is a subunit of LFA-1, a cell surface molecule involved in T cell mediated immune response.....
-
Chapter
Lipopolysaccharide (LPS)-Induced E-Selectin Expression and NF-кB Activation in Endothelial Cells Require Continuous Presence of LPS
Exposure of cultured human umbilical vein endothelial cells to lipopolysaccharide (LPS) causes increased expression of E-selectin (endothelial-leukocyte adhesion molecule-1, ELAM-1-by endothelial cells and con...
-
Article
Lipopolysaccharide-induced E-selectin expression requires continuous presence of LPS and is inhibited by bactericidal/permeability-increasing protein
Endothelial cells stimulated by LPS express E-selectin, which plays an important role in mediating neutrophil adhesion during inflammation. E-selectin is induced within 1–2 h, peaks at 4–6 h, and gradually ret...
